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ABSTRACT 
Tea; a product of Camellia Sinensis plant is the most broadly used beverage in the world. Tea 
phytochemicals have been studied for the prevention of various chronic diseases, such as cancer, 
obesity, diabetes, jaundice, hypertension and inflammation related disorders. Whereas many 
studies have revealed the potential efficiency of tea for the prevention of these physiological 
disorders, the underlying mechanisms remain unclear. In this work, we evaluated the evidence 
and discussed the significance of proposed mechanisms for the prevention of the diseases such as 
Alzheimer’s, obesity, diabetes mellitus type II, hypertension and asthma by tea. Molecular 
docking method was used to explore the ability of tea phytochemicals to inhibit the key enzymes. 
The three dimensional structure of target enzymes were either retrieved from protein data bank 
or modelled using swiss model. Autodock4.2 software was used for molecular docking that 
applies Lamarckian Genetic Algorithm. The ligand structures were retrieved from PubChem and 
KNApSAcK-3D database. PreADMET web server was used for Toxicity and ADME 
predictions. Based on this analysis, it has been found that theaflavin, rutin and 8-c-ascorbyl 
epigallocatechin could be the potential lead molecules as they act as inhibitor for most of the 
target enzymes and has a good drug score and also qualifies the toxicity and ADME test. Further 
the tea extract is loaded in liposomal drug delivery system and pectin-HEMA hydrogel system to 
analyse their drug delivery potential and it was found that liposomal system is best suitable for 
delivery to brain and hydrogel system better serve as colon specific delivery system. We 
concluded that these phytochemicals or their derivatives can be used for further in-vitro and in-
vivo studies to produce valuable lead drug candidates. 
Keywords: Phytochemicals, Molecular Docking, ADME & TOX, liposomal encapsulation, 
hydrogel
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CHAPTER 1: INTRODUCTION 
1.1- Introduction 
With all these technological inventions and advancement in science, we are capable of 
finding cure for the prevailing diseases and increasing our life longevity. But with each 
advancing day new diseases are coming into existence and we face new challenges every 
day to invent medicine and to protect ourselves. Due to changing life style we are facing 
many problems, diseases related physiological disorders that is due to environmental 
changes such as obesity, diabetes, jaundice, asthma and other diseases due to mutation. 
Still the challenge doesn’t end here. The medicines that are invented or come to market 
are not free from side effects. Each have some unwanted consequences, some are mild 
while others have deadly permanent consequences. To avoid all these consequences and 
to cure the diseases we need to search for some natural products. 
The medicinal use of natural compounds that are isolated or derived from different 
natural sources like plants, animals or micro-organisms; recorded in human history 
possibly from thousands of years. However, it was not until the nineteenth century that 
scientists isolated active components from various medicinal plants. Among all the 
various medicinal plants and herbs tea is the most ancient herb used by Chinese and it is 
the most extensively used beverage in the modern world. Thus now a days many 
researchers are making attempt to isolate the active compounds from tea for various 
specific diseases and making marketed drug products out of it.   
1.2- Tea and its phytochemicals : 
Tea is one of the most broadly consumed drinks worldwide due to its various reasons 
such as its easy availability, good taste and last but not least several health benefit for 
human consumption [1]. Two main categories of tea that dominates as beverage are black 
and green teas. Among them green tea is the non-fermented form of tea that is used 
mostly in China and Japan, while black tea is more prevalent in Europe, North America 
and India [2]. Another type named oolong tea is a transitional variant between the green 
type and black tea that is rich in catechins and oligomerized catechins [3]. The 
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commercially available tea variety is acquired from leaf of Camellia Sinensis plant. Two 
principal variety species of the plant are used one being the small-leaved Chinese variety 
plant (Camellia sinensis subspecies sinensis), grown extensively used in China and 
Japan, used for most other types of teas, and the other type is the large-leaved Assamese 
plant (Camellia sinensis subspecies assamica), predominates in South and South-East 
Asia, which was generally used as black tea, though in previous years some white and 
green have been produced [4]. Black tea is more oxidized than other types such as green, 
white and oolong teas. There are two ways of processing black teas. The Crush, Tear, and 
Curl method or orthodox method. In the CTC method fanings leaves or dust grades are 
produced. The method of orthodox processing is done either by hand or by machine. For 
production of high quality tea hand processing method is used.  
The usefulness of tea are credited to the presence of phytochemicals in it. Phytochemicals 
are the chemical compounds which naturally occur in plants. Some of the phytochemicals 
are accountable for colour and other organoleptic properties. The term phytochemical is 
usually used to refer to natural chemicals that may have significant biological properties, 
e.g.; antioxidants, and recognised as non-essential nutrients. The typical tea 
phytochemicals are epigallocatechin gallate, flavonoids, tannins, caffeine, polyphenols, 
boheic acid, theophylline, theobromine, anthocyanins, gallic acid. The extract from green 
tea has strong antioxidant due to the presence of (+)catechin, (-)-epicatechin (EC), (-)-
epigallocatechin, (-)-epicatechin-3-gallate and EGCG. Moreover, black tea leave 
production involves enzymatic oxidation of the polyphenols in tea leaf to various new 
products such as theaflavins and thearubigens. The chief theaflavins constituents in black 
tea are theaflavin, theaflavin monogallateA, theaflavin monogallateB and theaflavin 
digallate. Oolong tea is a partially oxidized type and hence retains a substantial amount of 
these catechins. These phytochemicals adds several advantages to tea one of them is the 
high antioxidant activities that is due to the presence of polyphenols which enable the tea 
to search free radicals. Because the tannins present in tea known to form bond with 
proteins, it has uses as anti-cancer, diuretic and anti-diarrhoeal effect. The tannins also 
have diuretic and anti-cancer activity. Tea appears to inhibit the cholesterol absorption 
hence helps in reducing cholesterol level. The stimulation effect by of caffeiene is the 
best know effect of tea. Caffeine works by affecting adenosine receptors and blocking the 
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phosphor-di esterase enzyme. Tea is also known to reduce cardiovascular disease and 
induce body weight loss. 
Hence using tea phytochemicals as ligand we can inhibit many enzymes that play vital 
role various disease pathways and thus can cure the disease. 
  
1.3- Enzymes: 
Till date tea is known to have activity on various enzymes that works in disease 
progression pathway. Some of those enzymes are acetyl cholinesterase, alpha amylase, 
alpha glucosidase, beta glucuronidase, pancreatic lipase and angiotensin converting 
enzyme. 
A. Acetyl cholinesterase  
AChE is a serine hydrolase enzyme that catalyses hydrolysis of the neurotransmitter 
acetylcholine (ACh), thus resulting in termination of ACh action at the cholinergic 
synapse. AChE has been the main focus of research aimed at the discovery of its 
effective inhibitors for their use in treatment of Alzheimer’s disease (AD). AD is the 
most common cause of dementia prevailing in our ageing society. It is estimated that 
AD account for 50 and 60% of dementia cases in old age and characterised by 
progressive, neurodegenerative disorder. The other symptoms linked to AD involve 
primary memory loss, decline in cognitive dysfunction and the late stages of the 
disease are often associated with language deficits, agitation, mood disturbances, 
depression and psychosis. Many drugs had been developed in recent years against AD 
but a total cure for the disease is not yet available and the drugs are often associated 
with long term side effects.  
B. Alpha Amylase  
The α–amylase; a family of endoamylases is one of the chief products secreted by 
salivary gland and pancreas. The enzyme plays a vital role in digestion of 
polysaccharides such as starch and glycogen by cleaving α-D-(1-4) glycosidic bonds 
and often found in plants, microorganisms and higher organisms. The enzyme α-
amylase action result in oligosaccharides with varying length with an α-configuration 
and α-limit dextrins as end products, which contains a mixture of maltotriose, maltose 
and branched oligosaccharides of 6–8 glucose units that constitues both α-1,4 and α-
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1,6 linkages. There are many other amylo-lytic enzymes which take part in the starch 
breakdown process, but α-amylase contribution is a prerequisite for the initiation of 
this process. 
C. Alpha Glucosidase 
It is a carbohydrate-hydrolase which releases alpha-glucose instead of beta-glucose.  
Alpha –glucose molecule is released by the enzyme, by hydrolysing the terminal non-
reducing 1-4 linked alpha- glucose residues. The substrate selectivity of the alpha-
glucosidase enzyme is because of sub site attractions of the active site of enzyme. 
There are two mechanisms proposed for enzyme’s action that include a nucleophilic 
displacement and an oxocarbenium ion intermediate pathway. 
Alpha-glucosidase inhibition play a vital role in treating type II diabetes and its 
inhibitors are marketed as oral anti-diabetic drugs that work by preventing the 
digestion of carbohydrates. Carbohydrates are converted into monosaccharide 
compositions that can be easily absorbed by the intestine. Thus, the inhibitors of 
alpha-glucosidase helps in reduction of the impact of carbohydrates in blood sugar 
thus work against type II diabetes.  
D. Beta Glucuronidase 
Beta-glucuronidase; a family-2-glycosyl hydrolase enzyme that chop the residue of β-
D-glucuronic acid from the non-reducing termini of glycosaminoglycan. In Homo 
sapiens, the lysosomal β-glucuronidase degrades sulphated glycosaminoglycans. The 
experimentally determined X-ray structure of a human β-glucuronidase shows that it 
is a tetramer, with each monomer having 653 AA residues and 80 kDa size. It was 
discovered that each monomer of the human. Several studies reported that the 
heightened activity of the enzyme lead to variety of pathological conditions, including 
urinary tract infection, renal diseases, transplantation rejection, epilepsy, neoplasm of 
bladder, testes, larynx, and breast. Among other therapeutic importance, one of the 
major advantage of this enzyme is its role in enterohepatic circulation and thus in 
jaundice. Jaundice; a disease characterized by yellowish discoloration of the skin, 
sclera, and mucous membranes due to elevated bilirubin as result of abnormal 
bilirubin metabolism and/or excretion.  
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A probable mechanism for controlling the bilirubin mechanism is β-Glucuronidase 
inhibitor which can interrupt circulation of the bilirubin in enterohepatic region and 
hence facilitates faecal excretion and lower serum bilirubin concentration. By 
inhibiting human milk β-Glucuronidase the intestinal absorption of the bilirubin is 
shown to decrease in a rat model with bile duct and duodenal catheters.  
E. Angiotensin Converting Enzyme 
ACE is a zinc-dependent mono-carboxypeptidase which plays a crucial role in 
balancing vasoconstrictor and proliferative actions of angiotensin II with the 
vasodilatory and ant proliferative effects of angiotensin. For the treatment of 
hypertension ACE is a important target because of the enzymes involvement in a 
number of blood pressure-related systems, for example’ the kinin nitric oxide system 
and renin-angiotensin system. In the RAS mechanism, angiotensin I is chopped into 
the potent vasoconstrictor angiotensin II by ACE, and the hypotensive peptide, 
bradykinin and kallidin are inactivated by ACE in KNOS. Therefore, unnecessary 
action of ACE results in increased vasoconstriction and hypertension. Altered 
expression of this enzyme is related to cardiac, vascular, and renal dysfunctions. In 
addition, blocking the synthesis of angiotensin II by ACE inhibitors or its actions by 
angiotensin II receptor blockers has shown to increase cardiac ACE expression. The 
overexpression of ACE by gene transfer technology protects the heart from 
hypertension-induced cardiac remodelling. Inhibition ACE is the potential 
mechanism for antihypertensive treatment.   
 
F. Lipase 
Lipases are the enzymes that help in triacylglycerol, phospholipids and fat digestion. 
The human lipases are two types that includes the pre-duodenal and the extra-
duodenal lipases. Pancreatic lipase (PL), is the major lipo-lytic enzyme produced and 
secreted by human pancreas, and it has a crucial role in the effective triglycerides 
digestion. PL eliminates fatty acids from the ‘a0’ and ‘a’ location of dietary 
triglycerides, producing mono-glycerides, saturated and polyunsaturated long chain 
fatty acids as the lipo-lytic yields. Lipase is accountable for 50–70% of dietary fats 
hydrolysis.  
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Inhibition of pancreatic lipase is one among the most broadly studied for determining 
potential efficiency of natural products as anti-obesity means. Orlistat, one among the 
two clinically accepted drugs for treatment of obesity, has mechanism of acting 
through PL inhibition. Being a best-selling drugs worldwide, still it has various 
unpleasant digestive side effects like oily stools, spotting among others. The success 
of orlistat has prompted research for the identification of newer inhibitors of lipase                                                                                                                                                                                                                  
that lack these disagreeable side effects. 
 
G. Lipoxygenase 
Lipoxygenase enzyme are found in different forms such as 5-lipoxygenase (5-LOX), 
15-lipoxygenase (15-LOX) etc. 5-LOX initiates the process of synthesis of the 
leukotriene (LTs) from arachidonic acid. LTs are known to cause constriction, 
increase vascular permeability and mucus secretion in the lung, and hence are potent 
vasoconstrictors of coronary arteries, and also have the potential to induce 
inflammatory reactions. Because of these properties, LTs are viewed as powerful 
mediators which may play crucial roles in inflammatory disorders, asthma, vascular 
diseases and cancer. The cellular catalysis reaction and expression of 5-LOX is 
regulated tightly. Hence, 5-LOX is found basically in mature leukocytes or dendritic 
cells. The cells which are unable to produce and express 5-LOX, their transcription 
system is blocked by DNA methylation. 
The (5-LOX) from Human has been considered since long as a probable therapeutic 
target for inflammatory diseases. While asthma being the principle disease target 
various other diseases have also been hypothesised in the research literatures as 
possible targets for 5-LOX inhibition, few named; allergic rhinitis, idiopathic 
pulmonary fibrosis, atherosclerosis, chronic obstructive pulmonary disease, atopic 
dermatitis ischemia reperfusion injury and acne vulgaris. 5-LOX is also an 
implication in seborrhoea dermatitis; a skin disease.  
Quite a number of inhibitors for 5-LOX have been found. The 5-LOX inhibitors are 
generally categorised into, reductive, iron ligands and competitive/mixed inhibitors. 
Till now only one chemical compound is being approved as one among the drug 
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against inflammation, i.e.; Zileuton. Zileuton is amongst a potent and selective 5-
LOX inhibitor but its mode of action is quite unusual for a therapeutic agent. 
 
1.4- Computational Drug Discovery: 
Computational drug discovery offers noble strategy for fast and frugal drug discovery and 
development technique. This technique diminishes efforts, time and cost of drug 
discovery and development. The recent improvements in bioinformatics and remarkable 
increase in the accessibility of both biological macromolecule and small molecule 
information has brought us significantly nearer to computational drug discovery. 
Various in silico approaches will assist in identifying various drug targets via 
bioinformatics tools. These tools even be familiarized to distinguish the target enzymes 
and assist in analysing their structures for probable binding sites. The computational 
method help in production of various candidate molecules, in the confirmation of their 
resemblance to other drug characteristics, these molecules and the target protein docking, 
ordering them consistently with their binding energies affinity, and finally further to 
enhance binding characteristics optimizing the molecules. Various web server and 
software are present that can be used for finding active site for example CASTp, Q site 
finder, pocket finder.  
For identification of a consistent and effective drug for target enzyme; protein-ligand auto 
docking are used. The main aim of protein-ligand docking is to calculate the binding 
energy of the protein-ligand reaction complex at given atomic coordinates. Recent 
growths in energy functions and search algorithms made computational docking 
approaches a valuable tool to discover and study the protein-inhibitor interaction  
The protein catalytic sites and active residues are the key factors for the flexible docking. 
Autodock4.2 software is an automated docking tool that help in predicting how the ligand 
molecules are binding to receptor of known 3D structure during docking and the software 
also allow to model the binding parameters of ligand with various number of different 
conformational clusters and finding possible minimum binding energy. 
The exploitation of available complementary experimental and informatics techniques 
intensifies the vision of success in several stages of the drug discovery procedure, starting 
from the identification of the novel targets and disclosure of their functions to the 
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discovery and development of principal compounds with preferred properties. Leading 
roles of computation in drug discovery are; Virtual screening, in silico ADME/T 
prediction & de novo design and advanced strategies for finding protein-ligand binding. 
 
1.5- Drug delivery Techniques: 
A. Liposomal Encapsulation 
The spontaneous formation of bilayered phospholipid membrane closed structures 
with internal aqueous environment when phospholipids are dispersed into water is 
known as liposome. They are small spherical shaped vesicles which can be produced 
from nontoxic surfactants, cholesterols, glycolipids, membrane proteins, and long 
chain fatty acids. 
The lipid based vesicles, i.e.; liposomes are microscopic (either unilamellar or 
multilamellar) vesicles which are formed due to phospholipids self-assembly in an 
aqueous media that results in closed bilayered structures. 
Liposomes are excellent agents for targeted drug delivery system as they can target a 
drug or any nanomaterial to the particular site of action in body thus helping in 
enhancing the efficiency. These vesicles can act as a reservoir from which the 
entrapped chemical/material is slowly released over time. Hence, to maintain 
therapeutic drug levels in blood stream a sustained release process can be exploited. 
Another advantage is that liposome surfaces can be modified by attaching 
polyethylene glycol (PEG) units to the lipid bilayer thus resulting in the increase of 
circulation time of liposomes in the bloodstream vividly. There is commercialization 
of liposomal formulations of anti-tumour drugs and antifungal agents nowadays. 
Molecules of various weight starting from low molecular weight compound such as 
glucose to high molecular weight macromolecules such as proteins and peptides have 
also being incorporated in liposomes. Aqueous compartments of the liposome 
contains water soluble contents while lipid soluble compounds/drugs and amphiphilic 
drugs/chemicals integrate themselves in the phospholipid bilayers of the liposome. 
Different routes of administration of liposome encapsulated drugs are intravenous 
injection, oral delivery, local application and these can be used for treating various 
diseases. 
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B. Pectin-HEMA Hydrogel 
Pectin consists of a complex set of polysaccharides, rich in galacturonic acid, found in 
the primary cell walls and is also one of the major component of the middle lamella, 
where it helps to bind cells together. The pectin is mainly used as a gelling agent, 
thickening agent and a stabilizer in food. It is also used to design medicines in the 
cases of high cholesterol, high triglycerides, and to prevent colon and prostate cancer. 
Pectin prevents poisoning caused by lead, strontium, and other heavy metals and is 
also administered in patients suffering from diabetes and gastroesophageal reflux 
disease. 
Hydroxyethylmethacrylate or HEMA is the monomer used in making the polymer 
poly hydroxyethylmethacrylate. This polymer is hydrophobic in nature; however, 
when subjected to water it swells due to the presence of hydrophilic pendant group. It 
absorbs from 10 to 600% water relative to the dry weight due to the hydrophilic 
nature. This swelling property of polymer, allowed it to be first material used in 
manufacture flexible contact lenses. 
Hydrogel is a hydrophilic network of polymer chains which sometimes can be found 
as a colloidal gel with water as dispersion medium. Hydrogels are highly absorbent 
natural or synthetic polymers that can contain more than 99.9% water. The degree of 
flexibility of hydrogels is very similar to natural tissue, because of their significant 
water content. Hydrogels are commonly used as scaffolds in tissue engineering. 
Hydrogel-coated wells known as “smart or intelligent gels” are environment sensitive 
and have been used for cell culture. These smart hydrogels have the capability to 
sense the changes in temperature, pH, or the concentration of metabolite and acts by 
releasing incorporated loads as result of such a change and a sustained-release drug 
delivery systems is achieved. 
 
1.6 - Objectives: 
The primary objectives of current project work are: 
1.6.1 To identify the different phytochemicals present in tea. 
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1.6.2 To analyse the phyto chemicals (from PubChem and knapsack Id) of selected molecule 
for their potential to be drugs. 
1.6.3 To analyse and dock all chosen molecules for the identification of novel drug candidates. 
1.6.4 To study molecular, ADME, toxicity properties of novel drug candidates. 
1.6.5 To design different drug delivery techniques and its characteristic analysis. 
 
1.7 - Plan of Work: 
 
Plan of work 7th Semester  8th Semester 
Mid sem End sem Mid sem End sem 
Literature Review     
Identification of 
tea 
phytochemicals 
    
Molecular 
docking and 
property analysis 
    
Drug Delivery 
techniques 
    
Manuscript 
writing 
    
 
 
 
 
 
CHAPTER 2: LITERATURE REVIEW 
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2.1 Diseases and the enzymatic pathways:  
2.1.1 Alzheimer’s diseases: 
A devastating neurodegenerative disorder with progressive loss in memory 
[5]. The enzyme responsible for Ach synthesis is significantly reduced 
resulting in decrease in levels of ACh in the brain. The site in AChE enzyme 
that is responsible for noncatalytic actions, is found out to be in the proximity 
of the peripheral anionic site (PAS) of the enzyme [6, 7]. Peripheral anionic 
site is a well-known site located at the entry site of the deep catalytic gap of 
the enzyme AChE, and it plays a vital role in binding inhibitors and 
substrates. 
Recently various efforts have concentrated on enhancing the transmission in 
cholinergic synapse by blocking the action of AChE which degrades ACh at 
the synaptic junction. AChE inhibitors (ChEIs) are the new targets for 
treatment of AD. Various ChEIs are available with varying degrees of 
efficacy, which slows down the dementia associated with AD [8-10]. The 
United States Food and Drug Administration (U.S. FDA) have been approved 
four drugs for treating the Alzheimer’s disease that act by inhibiting the 
AChE; those are Aricept, Exelon, Reminyl and Tacrine [11]. These four 
drugs represent diverse classes of AChE inhibitors and have different 
pharmacologic properties beyond inhibition of AChE. AChE inhibitors has 
various side effects which are usually attributable to marginal cholinergic 
effects that includes vomiting, nausea and diarrhoea. To decrease the side 
effects natural compounds should be considered for AD drug. Various 
research works have shown poly phenols such as cucumin, epigallocatechin-
3-gallate, reserveratrol and theaflavin, can be considered as alternative 
candidates for Alzheimer’s treatment. 
2.1.2 Diabetes Mellitus Type II: 
Diabetes mellitus type II is a common disease that affects people of all ages. 
Type 2 diabetes happens in genetically susceptible persons and is preferred 
12 
 
by weight excess [12-14]. Decreasing the absorption of dietary energy 
molecules such as fats and carbohydrates can ameliorate these metabolism 
related disorders. This can be achieved by inhibiting the significant enzymes 
that are responsible for metabolism of carbohydrates which includes alpha-
amylase and alpha glucosidase. 
Alpha amylase also known as α -1,4-glucan-4-glucanohydrolases is one of 
the chief products secreted from the human pancreas. The chief action of α-
amylase is the catalysis of early hydrolysis reaction of starch into smaller 
oligosaccharides by cleaving the α-D-(1-4) glycosidic bonds. Neither 
terminal glucose residues nor α-1,6-linkages can be cleaved by α-amylase 
[15-18]. The catalysis reaction of α-Amylase goes through a double 
displacement mechanism that involves the formation of covalent intermediate 
of β-glycosyl enzyme and its hydrolysis by the use of active site residue 
carboxylic acids [19, 20]. The residues, in particular, Asp197, Glu233, and 
Asp300 were defined to serve the purpose of catalytic residues [21, 22]. 
Acarbose, a marketed drug extensively used for treatment of type II diabetes 
mellitus, is a pseudo-tetra saccharide. The major side effects that are common 
to inhibitors of α-amylase; bloating, abdominal discomfort, diarrhoea and 
flatulence occur in about 20% of patients. 
The breakdown of carbohydrates in the small intestine can be prevented by 
using alpha-glucosidase inhibitors; and hence decreases the postprandial 
increase in level of blood glucose in humans [23-25]. For this attribute alpha 
glucosidase inhibitors can be used as potential medication targets for 
treatment of diabetes mellitus. Acarbose, voglibose and miglitol are the two 
marketed drugs that a help keep blood sugar levels within a target range by 
slowing the digestion of starches [26-30]. Alpha-glucosidase inhibitors are 
competitive inhibitors of the enzymes. Acarbose also blocks pancreatic alpha-
amylase in addition to inhibiting membrane-bound alpha-glucosidase. 
Pancreatic alpha-amylase hydrolyses complex starch structure to small 
oligosaccharides in the lumen of the small intestine. By inhibiting the 
enzymes rate of digestion of carbohydrate can be reduced. Less amount of 
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glucose is absorbed because the carbohydrates are not broken down into 
small molecules such as glucose. The short term effect of these drugs on 
diabetic patients is to decrease current blood glucose levels while the long 
term effect is a small reduction in haemoglobin A1C level. 
 
2.1.3 Obesity: 
Obesity is a multifaceted disease with symptoms of an excessive weight 
increase in comparison to height because of increased deposition of fat like 
adipose tissue that accredited to a higher calorie intake than expenditure of 
energy. Pancreatic lipase has a crucial role in the effective digestion of 
triglycerides and is accountable for the hydrolysis of 50–70% of total dietary 
fats [31, 32]. This enzyme has been widely used for the determination of the 
potential efficacy of natural products as anti-obesity agents [33]. Orlistat, the 
saturated derivative of lipstatin is the only authorized anti-obesity drug that 
has been shown to act through inhibition of pancreatic lipase (PL), which is a 
key enzyme for the digestion of dietary triglycerides [34]. 
2.1.4 Jaundice: 
Jaundice is a disease that characterized by yellowish discoloration of the skin, 
sclera, and mucous membranes due to elevated bilirubin as result of abnormal 
bilirubin metabolism and/or excretion. There are two type of bilirubin present 
in our body; the unconjugated or indirect bilirubin which is insoluble in water 
or conjugated to glucuronic acid/direct bilirubin which makes it soluble in 
water. Degradation of heme results in production of bilirubin that undergoes 
conjugation with glucuronic acid and excreted as bilirubin glucuronide via 
bile into the intestine. Intestinal β-Glucuronidase can chop the glucuronide 
bond to yield unconjugated bilirubin that can be absorbed by the intestine 
back into the blood circulation [35, 36]. Breast milk also contains some 
amount of beta-Glucuronidase that contributes in neonatal jaundice, because 
of its potential to de-conjugate bilirubin conjugates in intestine, yields 
bilirubin which is better absorbed by intestine [37]. 
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A probable mechanism for treating jaundice is β-Glucuronidase inhibitor 
which can interrupt the enterohepatic circulation of bilirubin by acting on its 
active site residue and thus facilitating excretion in faeces and serum bilirubin 
concentration is lowered [38]. The human β-glucuronidase active site residue 
has been found based upon the experimentally determined active site in E. 
coli β-galactosidase and corresponds to the amino acid residues Glu451, 
Glu540 and Tyr504.  Some of the presently marketed formulas based on this 
mechanism is enzymatically hydrolyzed casein [39]. Casein hydrolysate 
formula inhibits β-Glucuronidase, and infants consuming such formula have 
less jaundice than infants receiving routine formula [40, 41]. The major β-
Glucuronidase inhibitor in casein hydrolysate is L-aspartic acid [42]. Thus β-
Glucuronidase inhibitor are potential target for treatment of hyperglycaemia. 
2.1.5 Hypertension: 
Hypertension  or otherwise called high blood pressure, also sometimes known 
as arterial hypertension, is a prolonged medical disorder which is 
characterized by elevation in blood pressure in the arteries. Of several causes 
of hypertension one is the Angiotensin converting enzyme that plays a vital 
role in vaso-constriction and dilation and thus affects the blood pressure. 
ACE is a key target for the treatment of hypertension because of its 
involvement in a number of blood pressure-related systems, for example’ the 
renin-angiotensin system (RAS) and the kinin nitric oxide system (KNOS). In 
the RAS, the ACE cleaves angiotensin I into the potent vasoconstrictor 
angiotensin II, and in the KNOS, hypotensive peptide, bradykinin and 
kallidin are inactivated by ACE [43]. Therefore, unnecessary action of ACE 
results in increased vasoconstriction and hypertension. The mechanism of 
action of ACE shown below. Angiotensin-converting enzyme (ACE) 
inhibitors can be considered as potential agents for the treatment of heart 
failure, hypertension and other cardiovascular and renal diseases. ACE 
inhibitors have been proven more effective than other hypertensive 
substances in reducing proteinuria and retarding the progression of renal 
damage in patients with various types of nephropathy. Some of the synthetic 
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ACE inhibitory marketed drugs are Captopril, Lisinopril and Enalapril that 
act as anti-hypertensive [44]. However, pharmacological ACE inhibitors use 
results in a range of side-effects that includes cough, skin rashes, 
angioedema, reduced renal function and foetal abnormalities [45].  
 
Figure 1: Pathway of renin angiotensin system. 
 
2.1.6 Asthma: 
Asthma disease is characterized by episodic hyper secretion of mucus, 
bronchoconstriction and inflammation of the air passage. Several research 
studies suggest that compounds derived from the activities of arachiodonate 
5-lipoxygenase on arachiodonic acid have a role in the physiological pathway 
of asthma [46, 47]. The products of 5-LOX pathway include 5-HETE, 
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sulfidopeptide leukotrienes, have been detected in body fluids after induced 
Broncho-constriction [48]. Hence inhibition of these 5-LOX products may act 
as potential drug target for asthma treatment. Many inhibitors for 5-LOX 
have been described [49-51], that can be categorised into three types, iron 
ligands, reductive and competitive inhibitors [52], nevertheless, only one 
compound has been permitted as a drug, zileuton [53, 54]. Zileuton is a 
potent and selective 5-LOX inhibitor but its mode of action is unusual for a 
therapeutic [52, 55]. 
 
2.2 Drug Delivery Techniques: 
Method of administering a pharmaceutical compound to achieve a therapeutic effect in 
humans or animals is provided by various drug delivery systems. The technological 
inventions are necessary for administering drug at precise rate and also slow and targeted 
delivery are other attractive methods that have been pursued vigorously [56-58]. 
LIPOSOMAL DRUG DELIVERY SYSTEM 
The concentric bilayered lipid structures consist of amphipathic phospholipids. There are 
various classification of liposomes based on the number of bilayer such as MLV 
(multilamellar), SUV (small unilamellar), or LUV (large unilamellar). The liposomal size 
range varies from 0.025 μm to10 μm in diameter. Methodology of preparation and 
composition of ingredients regulates size and morphology of the resulting liposomes. 
Liposomal encapsulation are used for delivery of various compounds such as drugs, 
vaccines, and genes for a diversity of disorders [59]. Enhanced efficiency and reduced 
toxicity are provided by drug delivery systems. Long circulating macromolecular carriers 
such as liposomes are known to exploit the ‘enhanced permeability and retention’ effect 
for preferential extravasation from cancer vessels [60]. Stable formulation, improved 
pharmacokinetics, and a degree of ‘passive’ or ‘physiological’ targeting characteristics 
are provided by liposomal drug delivery systems [61]. Another category of liposome 
known as immune-liposomes appear to be non-immunogenic and are capable of long 
circulation even with repeated administration [62]. There are several studies showing 
liposomal encapsulated dopamine can be efficiently delivered into the brain and its 
degradation in circulation can be prevented [63]. The mechanism of action is that 
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liposomes get attached to the membranes of cell and fuse with them, then releasing the 
encapsulated drug into the cell. The other mechanism suggest that in phagocytic cells, 
liposomes are taken up, the phospholipid walls are acted upon by organelles called 
lysosomes, and the medication is released. Still the Liposomal delivery systems largely 
under experimentation; the precise mechanisms of liposomal action are under study, as 
the ways of targeted delivery to specific diseased tissue [64]. 
PECTIN-HEMA HYDROGEL SYSTEM 
The use of biodegradable polymers for the development of sustained and site-specific 
drug delivery system has increased dramatically over the past few decades. Synthetic 
polymers can be tailored to develop a wide range of properties thereby offering greater 
advantages than the natural ones. However the use of synthetic polymers in 
pharmaceutical formulations are restricted since their processing techniques are based on 
certain properties. Therefore, this has led to the demand for safer drug carrier systems. 
Hydrogels are the hydrophilic polymer networks that are swollen in water, but are not 
dissolved in it. These are three-dimensional cross-linked polymeric structures that are 
able to swell considerably in an aqueous environment and are proved to have an 
extraordinary capacity (>20%) for absorbing water within the polymeric network 
structure. It was observed by Ranjha et al that the swelling characteristics, pH sensitivity, 
and the biodegradability of these cross-linked hydrogels could be modified to desired 
extent by varying the monomeric compositions and degree of cross-linking and also by 
using other suitable polymer component [65]. Pectin is a heterogeneous, hydrophilic 
naturally occurring polysaccharides that are the major constituents of citrus by products 
and is widely used as a gelling and stabilizing agent in food, pharmaceuticals and 
cosmetics. Poly-HEMA was chosen to modify pectin as it is a well-known biomaterial 
and is the first one to be successfully employed in the biological use. The synthetic 
hydrogels prepared using these poly-HEMA is known to possess a high mechanical 
strength, a relatively high water content in swollen state, and resistance to various 
chemicals [66]. In addition to its non-toxicity, non-antigenic properties and good 
biocompatibility, molecularly engineered hydrogels based on pHEMA have shown to be 
potential carriers in drug delivery for water soluble anticancer drugs, including 5-
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fluorouracil, topical mitomycin-C, and cytarabine, and also in dental, ophthalmic, and 
neural tissue engineering applications. 
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CHAPTER 3: MATERIALS AND METHODS 
 
MATERIALS AND METHODS: 
3.1. Requisites: 
3.1.1 Bioinformatics softwares and tools used 
1. NCBI 
2. Protein Data Bank (PDB) 
3. CASTp 
4. PubChem 
5. ArgusLab 
6. PreADMET 
7. PRODRG2 
8. AutoDock4.2 
9. LigPlot+ 
10. UCSF Chimera 
3.1.2 Chemicals and Reagents used 
1. Lecithin-  HIMEDIA 
2. Cholesterol- HIMEDIA 
3. Chloroform-Rankem 
4. Methanol- Lobal chemie 
5. PBS 
a. NaCl- HIMEDIA 
b. KCl- Qualigen 
c. Na2HPO4- Qualigen 
d. K2HPO4- 
3.2. Insilico Study 
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3.2.1. Protein structure retrieval: 
The three dimensional structures of target enzymes were retrieved from PDB (Protein 
Data Bank; http://www.rcsb.org/pdb/). The enzymes selected for targeting the diseases 
have been compiled in Table 1. Miscellaneous ligands and other hetero-atoms like water, 
ions were removed from the protein models for active site predictions and further 
docking studies using Argus Lab Software. 
Table 1: Potential Drug targets to target various diseases. 
Enzyme Disease  Organism PDB Id 
Acetyl cholinesterase Alzheimer’s Homosapiens 4M0F 
Alpha-amylase Diabetes mellitus Type II Homosapiens 1HNY 
Alpha-glucosidase Diabetes mellitus Type II Homosapiens 2QMJ 
Beta- Glucuronidase Jaundice Homosapiens 1BHG 
ACE Hypertension Homosapiens 1O86 
Lipase Obesity Homosapiens 1LPB 
Lipoxygenase Asthma Homosapiens 3V92 
 
3.2.2 Modeling: 
To build 3D model of protein structure, Homology modeling was used that takes 
experimentally found structures of linked family members as templates. SWISS-
MODEL workspace; that is a Web-based integrated modeling expert system. For a 
given protein, an archive of experimental protein structures is examined to identify 
appropriate templates. On the basis of a sequence alignment between the template 
structure and the target protein, a three-dimensional model for the target protein is 
created. Model quality evaluation tools are used to estimate the reliability of the 
resulting models from SWISS-MODEL. 
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 Lipoxygenase enzyme doesn’t have good quality PDB structure as those contain 
multiple mutations. Hence its structure is modelled using SWISS-MODEL. First a 
new modelling project was created.   Then target sequence is inserted in FASTA 
format and the model was built by clicking on ‘BUILD MODEL’.  Homology 
modeling is currently the most accurate computational method to generate reliable 
structural models and is routinely used in many biological applications. 
Figure 2: Screenshot of protein model building in SWISS-MODEL. 
 
  
3.2.3 Protein Active Site Predictions: 
The active sites of targeted enzymes were predicted by using CASTp Calculations 
(Computed Atlas of Surface Topography of proteins). Amongst the predicted site, the 
site having the catalytic amino acids was chosen for the docking of the ligand. The 
catalytic amino acids of the each protein were analysed from UniProt 
(http://www.uniprot.org/). 
 
3.2.4 Ligand selection: 
The three dimensional structure of phytochemicals of black tea were screened from 
KNApSAcK-3D database (http://knapsack3d.sakura.ne.jp/), PubChem database 
(http://pubchem.ncbi.nlm.nih.gov/) and ChemSpider database 
(http://www.chemspider.com/). The PDB structure of the ligand was deduced using 
PRODRG Server (davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg). Ligand optimization 
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and energy minimization was further done using Argus lab software. Apart from this, 
the three dimensional structures of standard inhibitors for all the aforesaid proteins 
were also deduced from PubChem database (http://pubchem.ncbi.nlm.nih.gov/) and 
were used as reference inhibitory molecules. 
 
3.2.5 ADME properties and toxicity testing of ligands using PreADMET server 
An important block in the drug discovery process, particular in the later stages of 
drug discovery, is the analysis of the ADME and toxicity properties of the lead drug 
candidates. To avoid the failure of more than 50% of drug nominees because of 
ADME/Toxicity deficits most pharmaceutical corporations has employed a collection 
of in vitro ADME/Toxicity screening software that aims at discarding compounds 
within the discovery section which are seem to fail any down the line test. One of the 
web based application is PreADMET quickly predicts the drug-likeness and 
ADME/Toxicity knowledge of drug candidates. The web address 
http://preadmet.bmdrc.org/ was accessed to open PreADMET server. Chemical 
structure of ligand was drawn and submitted in the displayed screen. The result was 
saved carefully. 
 
FIGURE 3: Screen shot of molecular property analysis in Pre ADMET server. 
 
3.2.6 Molecular Properties and Drug likeness: 
The phytochemicals of tea were further examined for its drug likeness and molecular 
properties using Osiris web server. Molsoft; A Cheminformatics system which 
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provides varied range of software tools that supports manipulation of molecules and 
their processing, SD file conversion, molecule standardization, tautomer generation, 
molecule fragmentation, modeling of molecule and drug design, high quality 
molecule representation, database tools supporting sub-structure and search for 
similarity, also hold fragment-based virtual screening, bioactivity prediction and data 
visualization. The web address http://www.organic-chemistry.org/prog/peo/ was 
accessed to open molecular property viewer, i.e., Osiris. Then molecule structure was 
drawn and property were studied. 
 
FIGURE 4: Screen shot of Osiris molecular analysis web server showing molecular 
properties and drug score of theaflavin. 
3.2.7 Molecular Docking: 
The computational docking of black tea phytochemicals and standard inhibitors were 
performed into the active site of corresponding protein models using AutoDock4.2 
software (version 1.5.6). Lamarckian genetic algorithm is used as search function in 
the AutoDock 4.2 software. Lamarckian genetic algorithm is a fusion of genetic 
algorithm and local search algorithm which uses a parameterized scoring function of 
free energy to evaluate binding energy with regular docking procedure on the basis a 
150 arbitrarily placed individuals population size; a maximum number of 2.5*107 
energy evaluations, a mutation rate of 0.02, a crossover rate of 0.80 and an elitism 
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value of 1 [67]. For each ligand molecule 15 autonomous docking runs were carried 
out and the results that obtained were grouped according to rmsd criteria of 1.0 Ǻ. 
Autogrid calculates the grid maps that represents the proteins and grid size was set to 
60*60*60 points with grid spacing of 0.375 Ǻ. Polar hydrogen’s were added to 
protein macromolecular models during docking using the hydrogen’s module and 
then, Kollman united atom partial charges were assigned. The coordinate of the 
docked protein along with the ligand was visualized using UCSF chimera and 
LigPlot+ [68]. 
 
3.3 Drug Delivery Technique: 
3.3.1. Preparation of crude tea extract 
Dried tea leaves were collected, powdered and then 40g of the powder is added in 2ooml 
of water. Then it is boiled for 15min, filtered and the filtrate is dried in rotary vacuum 
evaporator at 30-35 rpm and 100⁰C. 3.5gm of powdered extract obtained after complete 
drying in Rotary Vacuum Evaporator. The powder is stored in deep refrigeration for 
further experimentation. 
  
3.3.2. Liposome Encapsulation 
A. Preparation of Encapsulated Liposome 
Liposomal Encapsulated tea was prepared by thin film hydration Method. In this 
method the lipid must first be dissolved and mixed in an organic solvent to assure a 
clear and homogeneous mixture of lipids. A solution is made of 6 ml chloroform and 
3 ml methanol to which 0.72g of lecithin and 0.06 of cholesterol is added. The 
solution is vortexed for 30-40 minutes till the lecithin and cholesterol is fully 
dissolved. This solution is added to round bottom flask of the rotatory vacuum 
evaporator. The temperature of the water bath attached to the rotatory vacuum 
evaporator is raised to 66 degree Celsius. The solution is rotated at 25 rpm till the all 
solvent gets evaporated and a thin lipid film is visible. 36 ml of PBS is prepared and 
0.36gm of powdered tea extract is added to it, then the solution is added to round 
bottom flask and the flask was vigorously vortexed till the entire film is dissolved in 
the aqueous medium. 
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Once the lipids are thoroughly mixed in the organic solvent to assure a clear and 
homogeneous mixture of lipids, then the solvent is removed to produce a lipid film. 
Then lipid film obtained is carefully dried to remove remaining organic solvent by 
placing the flask on a vacuum pump. Then medium of aqueous solution is added to 
the container of dry lipid and agitated. The hydrated lipid suspension was then 
downsized by a diverse techniques, such as extrusion or sonication. 
B. Characterisation of Liposome 
a. Downsizing of prepared liposomes: 
Disruption of LMV suspension using sonication typically produces SUVs. It can 
be done using bath or probe sonicators. Sonication of the prepared suspension is 
achieved by placing the liposomal suspension in a bath sonicators and then 
sonicating for 5 to 10 min above  of lipid. After sometime the liposomal 
suspension start to clarify to produce a slightly dim transparent solution. The haze 
produced in the suspension is because of scattering of light induced by remaining 
large liposome particles lingering in the suspension of lipid. To yield a clear 
transparent solution of small unilamellar vesicle these large residual particles are 
removed by centrifugation. Mean size of liposome and their distribution is 
inclined towards their concentration in solution, composition, time and power of 
sonication, temperature, sonicators tuning and volume. 
b. Phase contrast   microscopy: 
It is an optical microscopy method which is based on the principle of conversion 
of phase shifts in the incident light that is passing through a clear, transparent 
specimen to the intensity changes in produced image. Basic principle of the 
method is to make changes in phase observable in the phase contrast microscope 
by separating the background light illumination from the sample scattered lights 
that make up the forefront details and can be manipulated inversely. 
c. Zeta potential and Particle size measurement: 
A Zetasizer was used to analyse particle size by Dynamic Light Scattering and to 
measure Zeta Potential. Dynamic Light Scattering is a technique used to measure 
size of a molecule. The diffusion of the particles in the solution moving in 
Brownian motion is measured by DLS which is converted to size distribution and 
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size applying Stokes-Einstein equation. Smaller particle cause the intensity to 
fluctuate more rapidly than larger particle. The interference of scattered light from 
the particle causes a fluctuation in the intensity of light scattered at a particular 
observation angle which reflects particular size. DLS always gives hydrodynamic 
diameter; it is the value that denotes to how a molecule diffuses in a solution so it 
is mentioned as hydrodynamic diameter. 
d. Drug kinetics study: 
Drug release from the encapsulated liposomes was calculated using dialysis 
method.  
Preparation of dialysis bag: The glycerol included as humectant in the dialysis 
bag was removed by washing the dialysis tubing in running water for 3-4 hours. 
Removal of sulphur compounds can be done by treating the tubing with 0.3% 
(w/v) sodium sulphide solution at 80⁰C for around 1min. After that it is cleaned 
by the help of hot water wash (60⁰C) for approximately 2min. Then it is acidified 
with a 0.2% (v/v) water solution for removing the acid. 
Preparation standard curve: A standard curve for different tea concentration is 
prepared by analysing the concentration by OD method in UV-VIS 
spectrophotometer at 380nm. 
Liposomal concentration is dispersed in 1ml PBS solution and placed in a tube 
with one end covered with dialysis membrane. The tube was hung above a glass 
beaker containing 100ml of PBS inside it, for which the portion of the dialysis 
membrane with the formulation dipped into the PBS. The beaker was placed  in  
magnetic stirrer, then stirring was maintained at 100rpm at 37⁰C with samples 
were taken in every one hour over a course of 10 hours and assayed for drug 
content at 380nm spectrophotometrically.  
  
3.3.3. Pectin-HEMA Hydrogel 
a. Preparation of solution: 
Pectin solution of 1% concentrations was prepared by dissolving pectin in 
distilled water kept at 50⁰C. The temperature was gradually increased and set at 
70⁰C and then finally at 90⁰C. The solution was constantly stirred with the help of 
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a magnetic stirrer and a homogenous solution was prepared. The solutions 
prepared were further kept for degassing. Also, APS and TEMED solutions of 
40% strength was prepared. 
b. Preparation of Hydrogels: 
The hydrogels were prepared in 15 mL bottles that were purchased from Rankem. 
Hydrogels were prepared in these bottles to maintain the size and the uniformity.  
The preparation of the hydrogels were done by adding 1000 µL of the pectin 
solution of different concentration in 450 µL of the pure HEMA solution. Then 
after proper mixing of these two solutions, APS and TEMED both 25 µL were 
added respectively. A control was also prepared which did not contain any pectin. 
The total reaction mixture of 1.5 mL, was kept constant for all the different 
concentrations of pectin used. The prepared hydrogel solutions were then kept in 
a hot air oven at 37⁰C for the gels to form. 
c. Characterization of the hydrogels 
Swelling study at different pH 
The initial weight of the wet hydrogels were taken. These hydrogels were then 
kept in a Vacuum drying oven (Labtech) for around 48h to get fully dried. Dried 
hydrogels were then weighed (Wd) and immersed in (10) mL of pH 7.4 and pH 9 
phosphate buffer solutions and thus the swelling experiments were carried out. 
The hydrogels were taken out at different time intervals and blotted carefully to 
remove the excess surface water using laboratory tissue. These wet swollen 
samples were then weighed (Wt) at the above mentioned time intervals. All the 
swelling experiments at different pH were performed in triplicates. The swelling 
ration were calculated using the equation:  
Swelling ratio (%) =   %    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
where,  
 Wt= Weight of wet hydrogels,  Wd= Weight of dry   hydrogels 
e. Drug Release study: 
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Tea loaded pectin-HEMA hydrogel were prepared. The loaded hydrogel dispersed 
in 1ml PBS solution and placed in a tube with one end covered by dialysis 
membrane. The tube was hung above a glass beaker containing 100ml of PBS 
inside it, due to which the part of the dialysis membrane with the preparation 
immersed into the PBS. The beaker was placed in magnetic stirrer and the stirring 
was maintained at 100 rpm at 37⁰C with samples were collected every one hour 
over a period of 10 hours and assayed spectrophotometrically for drug release at 
380nm. 
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CHAPTER 4: RESULT AND DISCUSSION 
4.1. Insilico drug discovery: 
4.1.1 Modelling of Lipoxygenase 
The modelling of Lipoxygenase enzyme was done in Swiss model web server. Ten models 
were obtained which are subjected to further validation. The validation data is given below. 
Comparing the validation data of different properties model 8 is selected for further 
experimentation. Model 8 has 0% disallowed structural score, comparatively high 
Ramachandran plot score, highest percentage of allowed structural model and comparatively 
high verified structure.   
Table2: Verification of Lipoxygenase protein model. 
Model 
no. 
Ramachandran 
Plot score   
(%) 
Allow 
(%) 
Gener 
(%) 
Disallowed 
(%) 
Verified 
(%) 
Errat 
(%) 
1 92.9 6.6 0.3 0.2 95.56 82.432 
2 93.2 6.1 0.5 0.2 98.22 82.583 
3 93.4 6.1 0.2 0.3 97.93 85.435 
4 93.2 6.4 0.2 0.2 98.96 82.432 
5 93.1 6.3 0.5 0.2 95.7 84.685 
6 92.9 6.4 0.3 0.3 98.52 82.282 
7 93.2 6 0.3 0.5 96.89 83.634 
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8 93.2 6.4 0.3 0 96.89 87.234 
9 93.2 6.3 0.3 0.2 96.3 84.084 
10 93.2 6.3 0.2 0.3 98.96 83.033 
 
4.1.2 Active site prediction: 
Active sites of the target PDF protein of all organisms were predicted by CASTp, active site 
prediction tool. CASTp computation is based on the pocket algorithm of the alfa shape 
theory. The active site of protein with structural pockets and cavities were calculated for all 
test enzymes comparing the CASTp result and UniProt data. The result is shown below: 
Table3: Active site of the target enzymes. 
Name of 
enzyme 
Acetyl 
cholinesterase 
Alpha- 
Amylase 
Alpha-
Glucosidase 
Beta- 
Glucuronidase 
ACE Lipase Lipoxyg
enase 
PDB Id 4M0F 1HNY 2QMJ 1BHG 1O86 1LPB - 
Active site 
amino acid 
SER-203, 
HIS-447, 
GLU-334 
GLU233, 
ASP300 
ASP529, 
GLU532 
GLU451 GLU391 SER152 LEU608 
 
4.1.3 Docking study: 
As part of our ongoing effort towards the design and development of effective drug against 
most prevailing chronic diseases for subsequent use in medical applications, we have studied 
the inhibition efficiency of the selected black tea phytochemicals for the possible drug 
targets. The docking of protein with ligand molecules was done step by step according to the 
standard procedure. It was done by automated docking tool AutoDock4.2. In order to find the 
novel drug against each dieses under consideration first we docked those enzymes with 
reference molecule. The reference molecule that selected were marketed drugs which act in 
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selected inhibitory pathway. For most of the ligands, docking explicitly generated the 
crystallographic binding orientation within the protein cavity. For each ligand, 10 
independent docking run were initiated with randomized populations and docking results for 
individual run were clustered if their final docked positions were within a tolerance of 0.5 
A⁰. 
The docking result of enzymes of selected diseases with respective reference molecule are 
listed below: 
Table 4: Docking study of target enzymes with the reference molecules. 
ENZYME Name of 
Inhibitors 
B.E.(kcal/mol) IC (µm) 
Acetyl 
cholinesterase 
(4M0F) 
Donepezil -9.88 0.057 
Galantamine -9.24 0.17 
Rivastigmine -7.72 2.2 
Tacrine -6.99 7.53 
Huperzine -8.66 0.45 
Beta- 
Glucuronidase 
(1BHG) 
Saccharolactone -5.42 583.2 
       Silymarin -8.78 0.368 
Alpha- amylase Acarbose -5.04 202.9 
Lipase 
(1LPB) 
Orlistat -5.9 47.38 
Esculetin -6.7 12.35 
Alpha- 
glucosidase 
(2QMJ) 
Miglitol -6.82 9.98 
Voglibose -9.26 0.163 
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ACE 
(1O86) 
Benazepril -10.15 0.036 
Captopril -6.08 35.01 
Enalapril -7.94 1.51 
Lisinopril -10.52 0.019 
Temocapril -10.54 0.019 
Zofenopril -7.95 1.5 
Lipoxygenase 
(MODEL 8) 
Azelastine -4.4 594.5 
Carbamazine -5.54 87.64 
nerdihydro 
guaiaretic acid 
-5.54 86.63 
Zileuton -6.68 12.78 
 
The docking of enzymes with the selected candidate ligands were done at the respective active 
site of the enzyme. All the catalytic residues are present in active site pocket of the enzyme and 
thus helpful in stable interactive bond formation with ligand molecules. Docking result were 
interpreted on the basis of binding energy and inhibition constant.  This high binding energy 
suggest stable interaction thus a very high inhibition efficiency and low inhibition constant. 
Inhibition constant (Ki) value obtained from the docking result agrees with it. From all docking 
results we sort out top two docking result for each enzyme-ligand complex and represent in 
tabulated form below. We have sorted this result according to decreasing order of binding 
energy. 
Table 5: Best docked ligands and their UCSF chimera interaction analysis. 
ENZYME Name of test 
Inhibitors 
Binding 
Energy 
IC 
 (µM) 
H- 
Bonds 
Interacting Amino acid 
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(kcal/mol) 
Acetyl 
cholinesterase 
(4M0F) 
theaflavin 
(114777) 
-11.77 0.0068 8 TYR124 (3), GLY126, 
GLU202, ASN87, 
MET85, GLY448 
Vitamin E (2116) -10.77 0.0128 0 - 
DONEPEZIL* -9.88 0.0568 0 - 
Alpha- 
Amylase 
(1HNY)  
8-c-ascorbyl(-)-
epigallocatechin 
(3001587) 
-8.69 0.4289 6 HIS201, GLU233, 
ASP197, ARG195, 
Intramolecular(2) 
Rutin 
(5280805) 
-8.58 0.5177 6 GLU233, HIS305, 
HIS201, LYS200, 
TRP59(2) 
ACARBOSE* -5.04 202.91 8  
Alpha-
Glucosidase 
(2QMJ) 
orientin  
(5281675) 
-8.92 0.2899 5 GLN603, ASP327(4) 
8-c-ascorbyl(-)-
epigallocatechin 
(3001587) 
-7.57 2.8 7 ASP203, ASP327(3), 
TYR605, GLY604, 
Intramolecular (1) 
VOGLIBOSE* -9.26 0.1634 3  
Beta- 
Glucuronidase 
(1BHG) 
Theaflavin 
 (114777) 
-8.83 0.3358 3 GLU540, ASN450, 
SER503 
Strictinin 
 (73330) 
-8.81 0.3491 7 GLU540(2), ASN450, 
ASN484, GLU451, 
TYR508, LYS606 
Silymarin* -8.78 0.368
  
3 GLU540, TYR505, 
PHE206 
ACE 
(1O86) 
Theaflavin 
 (114777) 
-10.94 0.0095 9 SER355(2), TYR360, 
PHE359, ASN66, 
ASP358, ALA63, 
Intramolecular (2) 
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Rutin 
(5280805) 
-9.74 0.0723 8 ASN70, ALA356, 
TRP357, GLU411, 
GLU384, ARG522, 
TYR523, Intramolecular 
(1) 
RAMIPRIL* -11.07 0.0077 1  
Lipase 
(1LPB)  
8-c-ascorbyl 
epigallocatechin 
3-o-gallate 
(c00008969) 
-10.14 0.0371 5 SER237, HIS236, 
GLY161, ASP164(2) 
 
Schaftoside 
(442658) 
-9.78 0.0677 6 ASP164, SER137, 
ILE163(2), 
Intramolecular (2) 
ORLISTAT* -5.9 47.38 1  
Lipoxygenase Hexadecane 
(5366244) 
-6.75 11.27 0 - 
ZILEUTON* -6.68 12.78 0 - 
*Standard inhibitors 
4.1.4 Interaction study: 
As mentioned above, protein-ligand interaction analysis is necessary for better understanding of 
the underlying molecular mechanisms of this wide-ranging inhibitory activities of the candidate 
ligands against the target enzymes. To describe the enzyme-ligand complex stability the 
molecular interaction in terms of Hydrogen bond & hydrophobic interaction were studied using 
UCSF chimera and Ligplot. The result for only the best posture of each nominated potential lead 
molecules were presented below. A Ligplot figure gives a schematic representation of the 
hydrogen bonds and non-bonded interactions between ligand and the residues of the protein with 
which it interacts. Higher stability comes from higher binding affinity which in turn depends on, 
if the ability of ligands to form hydrophobic interactions with the binding site hydrophobic 
amino acids is higher. Figure below shows the interaction between the best selected ligands and 
the targeted enzyme. It can be seen that selected ligands have large number of H-bond and 
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hydrophobic interactions, where no. of H-bond is less there hydrophobic interaction number is 
higher and vice versa. 
Table 6: Interaction study of best docked ligand-target enzymes using LigPlot  
PROTEIN Active 
AA 
residue 
LIGAND H-bond Hydrophobic interaction 
Acetyl cholinesterase 
(4M0F) 
SER203 Theaflavin 
(114777) 
TYR133, GLN71, HIS497, ASN87, 
TYR124, GLY126 
GLY120, LEU130, GLU202, 
ILE451, TRP86, GLY448, 
GLY121, PRO88, TYR337, 
TYR341, TRP286, PHE297, 
SER125, PHE338, ASP74 
Vitamin E 
(2116) 
NA GLU202, SER203, HIS447, 
PHE338, TYR337, TRP286, 
TYR341, GLY122, PHE297, 
ASP74, TYR124, SER125, 
GLN71, TYR72, ASN87, 
TYR133, TRP86, GLY120, 
GLY121 
Alpha Amylase 
(1HNY) 
ASP197 8-c-ascorbyl(-)-
epigallocatechin 
(3001587) 
HIS305, ASP195, GLU233, ASP356 LYS200, HIS201, LEU162, 
TYR151, 
TRP59,TRP58,ASP300, HIS299, 
TYR62, ILE235 
Rutin 
(5280805) 
TRP59, GLU233, HIS201, LYS200, 
GLU233, HIS305, ASP356 
TYR62, LEU162, GLU63, 
TRP58, ASP19, ALA198, 
TYR151, GLY306, ILE235 
Alpha-Glucosidase 
(2QMJ) 
ASP443 8-c-ascorbyl(-)-
epigallocatechin 
(3001587) 
ASP327, GLN603, ASP203, MET144 TYR605, TRP406, TRP539, 
ASP542, ARG526, ASP443, 
TRP441, ILE364, HIS600, 
TYR299, PHE575 
Orientin 
(5281675) 
GLN603, ASP327 ILE364, TRP441, ASP542, 
ASP443, TRP406, PHE450, 
MET444, ASP203, ALA576, 
TYR299, TYR605, GLY602, 
PHE575 
Beta Glucuronidase 
(1BHG) 
GLU451 Strictinin 
(73330) 
HIS385, LYS606, GLU540, ASP207, 
ASN484, GLU451, ASN486 
TRP587, TYR508, SER485, 
HIS455 
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Theaflavin 
(114777) 
LYS606, TYR584, ASN450, HIS385 SER503, TYR508, HIS509, 
TYR205, GLU451, PHE206, 
GLU540, ASP207, TRP587 
ACE 
(1O86) 
GLU384 Theaflavin 
(114777) 
ASN66, TYR360, ASP358, SER355, 
HIS353, GLU384, TYR523 
TYR63, TRP357, ALA356, 
PHE391, ARG533, VAL518, 
PHE513, ALA354, GLU411 
Rutin 
(5280805) 
ASN70, ALA356, GLU384, HIS387, 
HIS383,GLU411,ZN701 
PHE513, VAL357, GLU143, 
HIS353, SER355, TRP357, 
ALA354, VAL380, PHE391, 
TYR520, GLU2000, TYR523, 
HIS543 
Lipase 
(1LPB) 
SER237 8-c-ascorbyl 
epigallocatechin 
3-o-gallate 
(C00008969) 
ASP164, ARG341, SER237, HIS236 LEU349, ILE163, PHE162, 
HIS348, TYR199, PRO265, 
PHE300, LEU298 
Schaftoside 
(442658) 
ARG341, PHE162, SER237 LEU349, ALA345, ALA344, 
ILE163, PHE300, TYR199, 
ILE294, HIS348, ALA263, 
GLY161, ASP164 
LIPOXYGENASE LEU608 Hexadecane 
(5366244) 
NA NA 
 
The pictorial representation of best docked molecule is in figure below. The right side figure 
shows the LigPlot+ analysis in which green dotted line shows the hydrogen bonding between the 
drug candidate and amino acid residues of protein . The purple coloured molecule is the drug 
candidate. In the UCSF Chimera analysis the orange and blue coloured line shows hydrogen 
bonding and the middle fluorescent molecule is the drug candidate and the side coloured ones are 
the amino acid of the protein within area less than 5 Å. The analysis of docked molecule were 
done and result shown in above table. 
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FIGURE 5: UCSF and LigPlot+ interaction analysis.  The left side figure show the UCSF 
chimera post-docking analysis, the middle green colored molecule represent ligand and yellow 
colored ones are the neighboring amino acids in 5 Å region that  are interacting with ligand. The 
right side figures exhibits the Ligplot+ result. In the LigPlot result; dotted line represents the H-
bond of the ligand with the amino acid of the protein represented in green. Spikes on the arcs 
show the hydrophobic interaction with the amino acids presented in black 
The results of table show hydrogen bonding between drug candidate and amino acid residues of 
target protein. Furthermore, from the UniProt we identified the active amino acid residue for 
each protein that is bonded with metal residue. The active metal binding amino acid residue is 
crucial for the function of protein. This residue directly participates in catalysis and if we hinder 
this residue to make bond with metal ion, the biological functioning of protein is totally busted. 
This will add plus point to docking result. The position of active metal binding residue in the 
protein sequence is also shown in the table. 
4.1.5 Molecular, ADME properties calculation and toxicity testing result: 
The molecular properties calculation of 2 best docked molecules was done by molsoft online 
server, the ADME properties calculation and the toxicity testing was done by PreADMET server. 
The Molsoft calculates the molecular weight, number of hydrogen bond donor, number of 
hydrogen bond acceptor, octanol-water partition coefficient (LogP), and solubility (LogS). The 
PreADMET calculates the absorption, distribution, metabolism, excretion and toxicity properties 
of drug candidates. 
Table 7: ADME and toxicity analysis of best docked ligands. 
Molecule 
Id 
Absorption Distribution Carcinogen
i- 
city test 
HIA 
(%) 
Caco-2 
cell 
(nm/se
MDCK 
cell 
(nm/sec) 
Skin 
(
PPB 
(%) 
BBB 
(%) 
Mou
se 
Rat 
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c) ) 
Theaflavin 
(114777) 
17.867 14.818 0.04596 -4.52829 100 0.036 -ve -ve 
Vitamin E 
(2116) 
97.832 29.119 38.9051 -0.51599 100 19.90 -ve -ve 
8-c-ascorbyl(-)-
epigallocatechi
n 
(3001587) 
4.7156 5.8293 0.70946 -4.62943 39.6 0.028 -ve -ve 
Rutin 
(5280805) 
2.8612 7.9126 0.32694 -4.6667 43.9 0.029 -ve -ve 
Schaftoside 
(442658) 
4.2104 6.708 0.522638 -4.79521 39.6 0.028 -ve -ve 
Orientin 
(5281675) 
14.99 2.995 0.6968 -4.68557 63.1 0.034 -ve -ve 
Strictinin 
(73330) 
0.822 12.854 0.09971 -4.32686 100 0.03 -ve -ve 
8-c-ascorbyl 
epigallocatechi
n 3-o-gallate 
(C00008969) 
1.573 11.716 0.04342 -3.94587 100 0.03 -ve -ve 
Hexadecane 
(5366244) 
100 37.788 66.1719 -0.52629 100 18.63 -ve -ve 
 
The above tables reveal the properties of molecule as a potent drug candidate. All molecules 
have well moderate Caco-2 cell permeability, low MDCK cell permeability, human intestinal 
absorption, weakly bound to plasma protein and inactive BBB penetration. All of these molecule 
show negative result in carcinogenicity test. 
Table8: molecular property and drug likeness study of best docked ligands. 
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Ligand Structure M.W
. 
Clog
P 
Solubilit
y 
(Log S) 
Drug-
likenes
s 
Drug
-
score 
Theaflavin 
(114777) 
 
564 -1.02 -3.16 2 0.46 
Rutin 
(5280805) 
 
610 -1.26 -2.4 3.31 0.57 
Orientin 
(5281675) 
 
448 -0.42 -1.97 -0.71 0.32 
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Schaftoside 
(442658) 
 
564 -1.9 -1.81 -5.83 0.12 
Isoschaftoside 
(3084995) 
 
564 -1.89 -1.81 -5.83 0.16 
8-c-ascorbyl(-
)-
epigallocatechi
n (3001587) 
 
480 -1.54 -1.25 1.82 0.72 
8-c-ascorbyl 
epigallocatechi
n 3-o-gallate 
(C00008969) 
 
646 -0.66 -2.05 -1.39 0.5 
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Molecular properties of the best ligands screened from docking analysis are shown in Table2. 
The hydrophilic property of a ligand is determined by cLogP.  Low hydrophilicity results in high 
logP value which signifies poor permeation or absorption. For compounds to have a rational 
probability of being well absorbed their logP value must not be greater than 5.0 
(http://www.organic-chemistry.org/prog/peo/).  In our result all the best candidate ligands exhibit 
value less than 5.0 and thus can be concluded to have good permeability. The calculation of 
LogS was done to evaluate the aqueous solubility of the ligand molecule which is a necessary 
condition for the knowledge its absorption and distribution. As per the given parameters LogS 
value should be greater than -4.0 and all the selected candidate molecules have values 
accordingly thus qualifies the test.  A positive value in the druglikeness test shows that the 
molecule contains predominantly fragments that are commonly present in commercially 
available drugs. But a negative score does not necessarily mean that the molecule cannot be a 
potential drug. At the end a drug score is calculated for each molecule which is a result obtained 
from combine outcome of cLogP, solubility, druglikeness, molecular weight and toxicity risks 
that may be used to judge the molecule’s overall probability to qualify as a drug.  
From the docking analysis it is observed that Theaflavin (114777), Strictinin (73330), Rutin 
(5280805), Orientin (5281675), Schaftoside (442658), Isoschaftoside (3084995), 8-c-ascorbyl(-)-
epigallocatechin (3001587), and 8-c-ascorbyl epigallocatechin 3-o-gallate (C00008969) could be 
the probable lead molecule for the inhibition of the target enzymes. Comparing the molecular 
properties tabulated above it can be observed that 8-c-ascorbyl(-)-epigallocatechin, and 8-c-
ascorbyl epigallocatechin 3-o-gallate have very good drug score. On the other hand theaflavin 
has a considerable overall drug score and have good inhibition efficiency for most of the target 
enzymes.  
4.2. Drug delivery Techniques: 
4.2.1 Liposomal Encapsulation: 
Particle size Analysis 
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FIGURE 6: Liposome; viewed under Phase contrast microscope. 
The above figure shows the liposomes as seen under phase contrast microscopy. The droplets 
depicts the bilayered liposomal structure.  
 
FIGURE 7a: Average size characterisation of the liposome (particle size distribution by 
intensity) 
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FIGURE 7b: Statistics graph of average size characterisation of the liposome (particle size 
distribution by intensity) 
 
FIGURE 8a: Average size characterisation of the liposome (particle size distribution by volume) 
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FIGURE 8b: Statistics graph (particle size distribution by volume). 
The liposome size was found out by dynamic light scattering method. The result shows the size 
distribution in two different method, one by volume and another by intensity. Size distribution by 
intensity shows a broad peak with Z average of 224.5 nm. The z-average diameter values are the 
means of 3 repeat measurements made on the neat liposome samples. The size distribution by 
volume agrees with that of intensity. The size of the liposomes can be varied and downsized 
liposome can be obtained by increasing the sonication time. 
Zeta Potential 
 
FIGURE 9: The zeta potential data of prepared liposome. 
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Zeta potential result shows that the encapsulated liposome has the potential -18.5 mV. To be 
stable the zeta potential value need to between -30 mV to -40 mV. The prepared liposome is less 
stable and the stability can be increased by pH adjustment and salt addition. The importance of 
characterization of liposomal encapsulation is understanding their appropriateness for a diverse 
range of applications. Knowledge about zeta potential of liposome in solution help in predicting 
the stability and fate of the liposomes in vivo. Stability and aggregation of liposomes in solution 
due to association of the liposomes with other counter charged particles can be checked by 
measuring zeta potential of the subsequent complex. 
Drug kinetics 
Table9: Drug release study: data for standard graph 
Conc. 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 
OD 
(380n
m) 
0.1057
44 
0.1954
11 
0.343
3 
0.4283
38 
0.5067
83 
0.6724
45 
0.7686
45 
0.7983
33 
0.8867
02 
1.1731
53 
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FIGURE 10: Standard graph depicting change in OD with increasing tea concentration.  
Table 10: Drug release study in liposomal encapsulated tea. 
Time 
(hr) 
1 2 3 4 5 6 7 8 9 10 
Drug 
release  
0.2 0.32 0.4 0.55 0.64 0.76 0.84 0.9 1.07 1.09 
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FIGURE 11: Test graph depicting drug release with time. 
The drug kinetic study was done for 10 hours and it shows the drug release increases over time 
and after it achieves equilibrium and the curve achieves equilibrium. The highest amount 
released is approximately 0.95mg/ml. The drug release was found to be good as the inhibitory 
concentration needed for various diseases studied above by in silico analysis was in the range 
microgram. Hence this drug delivery system serves better release of drug for colon specific 
delivery. 
4.2.2 Pectin-HEMA hydrogel: 
Swelling Test 
Table 11: Swelling test of pectin-HEMA hydrogel at pH 7 
Time Swelling %  
Hrs (at pH 7,  
37C) 
P0 Error P1 Error 
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0 0 0 0 0 
1 31.82931 5.8024 38.98804 4.07622 
2 43.37992 6.18436 50.82303 1.9238 
3 51.60138 6.26902 60.52184 3.68645 
6 66.90237 10.20625 74.86602 11.94019 
12 77.21329 16.39145 85.96142 18.79971 
24 86.75034 24.88078 93.56734 21.23649 
48 93.43828 27.45256 100.3104 20.18558 
 
 
FIGURE 12: Swelling data distribution at pH 7. 
Table 12: Swelling test of pectin-HEMA hydrogel at pH 9. 
Time Swelling Percentage (%) 
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Hrs 
(at pH9) 
P0 Error P1 Error 
0 0 0 0 0 
1 30.83345 1.26226 33.03208 0.82556 
2 36.39013 1.34182 38.84771 0.99467 
3 39.96303 1.01155 43.10153 1.74044 
6 47.48652 0.50946 53.039 4.95752 
12 50.67339 0.72345 57.99038 6.25878 
24 52.67239 3.60201 61.80925 4.57658 
48 57.96818 3.19823 69.22172 5.03515 
 
 
FIGURE 13: Swelling data distribution at pH 9. 
Swelling studies were done in phosphate buffer solutions of varying pH 7and 9. Results showed 
that swelling increased with increasing time. P0 denotes the control sample while P1 is the 
sample with drug. P1 swelling increases more with time than the control. It can be seen that test 
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sample swells more than the control and with increasing pH swelling decreases. At pH 7 the 
maximum swelling is approximately up to 100gm while at pH 9 maximum goes up to 70 gm.  
Swelling decreased with increase in crosslinking ratio owing to tighter hydrogel structure. 
Drug Kinetics 
 
FIGURE 14: Standard graph of drug release. 
The drug release study of pectin-HEMA hydrogel system was done for 10 hours and it shows the 
drug release increases over time and after it achieves equilibrium and the curve become parallel 
to x-axis. The highest amount released can be found out by comparing the test graph to standard 
which is approximately 1mg/ml. The drug release was found to be good as the inhibitory 
concentration needed for various diseases studied above by in silico analysis was in the range 
microgram. Hence this drug delivery system serves better release of drug. 
Table 13: Drug release study of tea loaded pectin-HEMA hydrogel. 
Time 1 2 3 4 5 6 7 8 9 10 
Drug 
Release 
0.36 0.49 0.59 0.7 0.76 0.94 1.09 1.11 1.13 1.14 
 
53 
 
 
FIGURE 15: Test graph of drug release from pectin-HEMA hydrogel 
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CHAPTER 5: CONCLUSION 
5.1 Summary: 
 In the current study tea phytochemicals are analysed for their therapeutic potential and 
specific phytochemicals for inhibition of target enzyme (acetyl cholinesterase, alpha 
amylase, alpha- glucosidase, beta glucuronidase, lipase, angiotensin converting enzyme 
and lipoxygenase) has been developed that can be used for further in-vivo analysis 
against respective diseases.  
 Initially 149 phytochemicals from tea were tasted for their molecular property, toxicity 
and drug likeness and 19 molecules are found out to be non- toxic and non- carcinogenic. 
 The docking analysis of these 19 phytochemicals against target enzymes show that 
theaflavin, rutin, schaftoside, strictinin, orientin, Vitamin E, 8-c-ascorbyl epigallocatechin 
3-o-gallate and 8-c-ascorbyl epigallocatechin play a vital role in their inhibition.  
 Among these best docked ligands for all the enzymes and the respective diseases, it was 
found that theaflavin and rutin are common inhibitory molecules for most of the enzymes 
that were under study. 
 The two best docked ligands for each enzyme were further subjected to interaction 
analysis using LigPlot and UCSF chimera. The interaction study reveals that the protein-
ligand complex were stable because of hydrogen bond and hydrophobic interaction with 
the active site residues. 
 Two drug delivery systems were prepared and analysed for target specific delivery. 
Liposomal encapsulation system was characterised and particle size was found to be in 
nano range with ales stable zeta potential value which can be increased by specific salt 
addition.  Drug release study was done by encapsulating tea extract in liposomes and the 
results shows that the system releases tea extract approximately up to 1mg/ml. liposomal 
encapsulation is best suitable for drug delivery to brain. 
 Pectin-HEMA hydrogel system was prepared and characterized by swelling test and drug 
release study was done. Swelling test in two different pH reveals that the hydrogel swell 
more in neutral system and the test sample showed more swelling than control sample. 
This system is best suitable for colon specific drug delivery. 
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5.2 Conclusion: 
Lower binding energy and inhibition constant are the key factors for the selection bet 
inhibitor. From the docking analysis it was found that theaflavin, rutin, schaftoside, strictinin, 
orientin, Vitamin E, 8-c-ascorbyl epigallocatechin 3-o-gallate and 8-c-ascorbyl 
epigallocatechin play a vital role in the inhibition of target enzyme. Out of the above 
mentioned molecules theaflavin rutin and 8-c-ascorbyl epigallocatechin show a good drug 
score and are common inhibitory molecule for most of the target enzymes. Hence all the 
outcomes suggest that these molecules can be act as potential drug targets and considered 
further in vivo analysis for production of drug. Two Drug delivery systems liposomal 
encapsulation system and pectin-HEMA hydrogel were prepared and analysed for proper 
characteristics. Liposomal encapsulation system was characterised and particle size was 
found to be in nano range with moderately stable zeta potential value which can be increased 
by specific salt addition.  Drug release study was done by encapsulating tea extract in 
liposomes and the results shows that the system releases tea extract approximately up to 
1mg/ml. liposomal encapsulation is best suitable for drug delivery to brain. Hydrogel system 
was prepared and characterized by swelling test and drug release study was done. Swelling 
test in two different pH reveals that the hydrogel swell more in neutral system and the test 
sample showed more swelling than control sample. This system is best suitable for colon 
specific drug delivery. 
5.3 Future Outlooks: 
The emerging new diseases with changing life style, the rising cost of development of drug 
and the lack of potential therapeutic representatives have been a chief concern now a days. A 
satisfactory potential substitute method is required as a solution of efficiency and wellbeing. 
In silico designing of drug molecules is one of the solution to the above problem which plays 
a vital role in different steps of development of a drug that is from pre-clinical procedure to 
late-clinical stage. This technological era has gifted a CADD that is, computer aided drug 
design as a novel work which starts with virtual screening and progress towards in-vitro and 
then in-vivo study. The various tools of bioinformatics helped in identifying potential drug 
molecules to target against different diseases. In this work the discussed drug molecules can 
be subjected to next step analysis to develop a new medicine.  
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